Table 3 Functions and canonical pathways as differentially expressed up-regulated genes in ob/ob vs. WT, with no significant changes in POKO vs. WT mice
Top Bio Functions | ||
|---|---|---|
Name | p-value | # Molecules |
Diseases and Disorders | ||
Immunological Disease | 7.66E-18 - 3.63E-03 | 250 |
Inflammatory Disease | 5.95E-15 - 3.60E-03 | 263 |
InflammatoryResponse | 2.28E-14 - 3.63E-03 | 144 |
Skeletal and Muscular Disorders | 4.99E-12 - 3.63E-03 | 255 |
Connective Tissue Disorders | 7.78E-12 - 2.44E-03 | 175 |
Molecular and Cellular Functions | ||
Cellular Development | 1.45E-17 - 4.37E-03 | 197 |
Cellular Function and Maintenance | 2.21E-15 - 3.58E-03 | 103 |
Cell-To-Cell Signaling and Interaction | 9.41E-15 - 4.37E-03 | 202 |
Cellular Growth and Proliferation | 3.93E-13 - 3.11E-03 | 173 |
Cellular Movement | 1.94E-09 - 3.78E-03 | 143 |
Physiological System Development and Function | ||
Hematological System Development and Function | 3.63E-16 - 4.04E-03 | 189 |
Hematopoiesis | 3.63E-16 - 3.27E-03 | 112 |
Tissue Morphology | 2.59E-15 - 3.60E-03 | 124 |
Cell-mediated Immune Response | 1.22E-14 - 3.78E-03 | 92 |
Immune Cell Trafficking | 2.25E-13 - 3.78E-03 | 118 |
Top Canonical Pathways | ||
Name | p-value | Ratio |
Autoimmune Thyroid Disease Signaling | 3.06E-13 | 17/61 (0.279) |
Allograft Rejection Signaling | 1.49E-12 | 16/59 (0.271) |
Type I Diabetes Mellitus Signaling | 4.79E-12 | 27/119 (0.227) |
Graft-versus-Host Disease Signaling | 3.57E-10 | 15/49 (0.306) |
B Cell Development | 8.43E-10 | 12/37 (0.324) |